【Product Description】 REMOTEMED C1 cardiovascular tester measures four important health data in 30 seconds: • lead electrocardiographs (ECG) • Blood oxygen concentration (SpO2) • Heart rate (HR) • Blood pressure trend (BP) The operation is not restricted by the site. It is a portable device that can independently measure by ordinary users by simply placing your finger on the electrode without the need for sticky electrode gel. 【Intendent use】 This device does not provide diagnostic functionality but can be used as a reference for personal cardiovascular health. Users can obtain the following values through this device: • lead electrocardiogram: Analyzes potential cardiovascular health risks for QRS wave abnormalities. • SpO2 blood oxygen concentration: Alerts to potential hypoxia. • Heart rate: Provides warnings for symptoms such as tachycardia, bradycardia, and arrhythmia. • Blood pressure: Systematically records health data, aiding in long-term monitoring of health status. This device is suitable for individuals who need to monitor their heart activity for slight rhythm changes or conduction disturbances during daily activities. It provides a personal health passport with long-term records of heart function information. It also provides reference information for healthcare professionals to obtain the user's daily cardiovascular health. Note: 1. The device records a 30-second I-lead electrocardiogram in real-time, providing a quick assessment of whether the user has arrhythmia, bradycardia (heart rate below 50 BPM), or tachycardia (heart rate above 100 BPM). 2. The results of the various measurements provided by this device are for reference only. Detailed information on cardiac rhythm still requires professional medical assistance. If there are any concerns, it is important to seek professional help from a medical institution. 【Function】 This product uses electrode pads to form a circuit through the user's hands, allowing it to measure and record Lead-I ECG. In addition, it uses an optical module to obtain PPG signals and calculates and displays real-time heart rate, SpO2 value, and blood pressure on the OLED screen or mobile app. It is a portable device designed for daily self-health management measurement. 【Features】 1. Records real-time I-Lead ECG data for 30 seconds, providing preliminary analysis for use as a basis for medical consultations. 2. Displays real-time HR rhythm for quick assessment of abnormal heart rhythms, bradycardia (heart rate below 50 BPM), and tachycardia (heart rate above 100 BPM). 3. Displays real-time SpO2 blood oxygen concentration, and alerts users if the measurement falls outside the reference range of 94-99%. 4. Provides reference values for blood pressure, allowing for long-term tracking of health status. 5. Integrated system design displays measurement instructions, processes, and results in real-time on the OLED screen of the device or smartphone. 6. Lightweight, portable, non-invasive measurement that can be taken anywhere, anytime, without any venue restrictions. 7. Given the sudden onset of cardiovascular-related illnesses, traditional 12-lead ECG machines can only be used in medical institutions and cannot be used for real-time self-monitoring. The REMOTEMED C1 Cardiovascular Tester can record Lead-I ECG data in real time. 1. A big data AI mining ECG product that meets FDA regulatory requirements. 2. A portable cardiovascular monitoring product with four functions (ECG, SpO2, HR, BP). 3. Senior-friendly, with the ability to display readings on the device, as well as playback, track, and share on mobile devices. 4. Optical blood pressure detection system, which differs from traditional strap blood pressure meters and does not cause discomfort. 5. Patients can measure their own ECG in real-time, solving the problem of traditional 12-lead ECG machines that can only be used in medical institutions and cannot record sudden discomfort outside of the hospital. SmartChip Microelectronics Corp. (SMC) is a company that specializes in medical devices and has research and development, production, marketing, and sales and service teams. The company initially focused on RFID applications and is now committed to OEM/ODM. It is expected to obtain TFDA QMS certification in 2023. With the SaMD product verification of the APPLE Watch, cardiovascular diseases seem to suddenly appear out of nowhere, causing many families to suffer. In fact, there are signs in daily physiology, and the company has decided to develop portable medical products that individuals can self-measure. Cardiovascular diseases often cause sudden discomfort. Traditional twelve-lead electrocardiograms can only be recorded by attaching electrode patches in medical institutions and cannot be self-measured by patients. 1. Passing the QMS certification and completing testing and verification, such as safety regulations, EMC, software verification, and functional verification, the company submitted an application for TFDA medical device Class II market approval. 2. It is expected to be sold in Taiwan and Southeast Asia, and the estimated revenue is expected to increase by NT$80 million after completion. 3. It is expected to increase employment by 10 to 15 people this year and is expected to obtain a 513g inquiry for US medical devices this year.